PCM
PRTK

Prelude Capital Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Prelude Capital Management’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-756
Closed -$4K – 2496
2020
Q2 		$4K Buy
+756
New +$3.36K ﹤0.01% 1763
2020
Q1 		– Sell
-1,965
Closed -$8K – 2176
2019
Q4 		$8K Sell
1,965
-475
-19% -$1.65K ﹤0.01% 1732
2019
Q3 		$11K Sell
2,440
-57
-2% -$228 ﹤0.01% 1488
2019
Q2 		$10K Sell
2,497
-93
-4% -$442 ﹤0.01% 1408
2019
Q1 		$14K Sell
2,590
-67
-3% -$433 ﹤0.01% 1366
2018
Q4 		$14K Buy
2,657
+2,073
+355% +$15.7K ﹤0.01% 1307
2018
Q3 		$6K Sell
584
-1,474
-72% -$14.9K ﹤0.01% 1619
2018
Q2 		$21K Sell
2,058
-262
-11% -$2.96K ﹤0.01% 1351
2018
Q1 		$30K Sell
2,320
-18,728
-89% -$279K ﹤0.01% 1206
2017
Q4 		$377K Buy
21,048
+442
+2% +$9.22K 0.03% 487
2017
Q3 		$517K Buy
20,606
+69
+0.3% +$1.61K 0.05% 368
2017
Q2 		$495K Sell
20,537
-13,788
-40% -$305K 0.05% 334
2017
Q1 		$661K Buy
34,325
+15,486
+82% +$244K 0.06% 303
2016
Q4 		$290K Buy
+18,839
New +$245K 0.04% 449

Other funds holding PRTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BC
Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prelude Capital Management's PRTK Position: Q3 2020 in Review

Prelude Capital Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2020, closing a stake of 756 shares — an estimated $4K sold.

Prelude Capital Management first reported a position in PRTK in Q4 2016 and held it in 14 quarters. The position peaked at $661K in Q1 2017. 100 funds tracked by Wall St. Rank hold PRTK as of Q3 2020.

  • Prelude Capital Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 756 Paratek Pharmaceuticals, Inc. shares in Q3 2020, an estimated $4K.
  • Prelude Capital Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 14 quarters.
  • Prelude Capital Management's Paratek Pharmaceuticals, Inc. position peaked at $661K in Q1 2017.
  • 100 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.